U.S. Shareholder Seeks To Block Millennium Takeover By Japan’s Takeda
This article was originally published in PharmAsia News
A shareholder of the U.S. biotech Millennium Pharmaceuticals has filed a suit to block a takeover by Takeda Pharmaceutical. The suit's backers are attempting to attract enough other shareholders to expand the suit to class action status. Their main complaint is the friendly takeover offer if $8.8 billion is below what the company is worth, even though the offer is the largest ever made by a Japanese drug maker for a foreign firm. The single suit was filled in Millennium's home state of Massachusetts. (Click here for more
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.